TCRT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.019

Open

2.975

VWAP

2.91

Vol

17.46K

Mkt Cap

69.60M

Low

2.850

Amount

50.75K

EV/EBITDA(TTM)

--

Total Shares

24.42M

EV

7.12M

EV/OCF(TTM)

--

P/S(TTM)

2.03K

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Show More

Events Timeline

(ET)

2026-05-26

11:10:00

Alaunos Therapeutics Reports Preclinical Readout for ALN1003

2026-05-18 (ET)

2026-05-18

08:30:00

Alaunos Therapeutics Updates Preclinical Data on ALN1003

2026-05-04 (ET)

2026-05-04

16:40:00

Valion Bio Appoints Melinda Lackey as General Counsel

2026-03-02 (ET)

2026-03-02

06:40:00

Alaunos Therapeutics Releases Early Data on ALN1003

2025-06-23 (ET)

2025-06-23

08:05:06

Alaunos prices 610,399 shares at $3.36 in registered direct offering

News

NASDAQ.COM

05-28NASDAQ.COM

Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement

stocktwits

05-26stocktwits

Alaunos Therapeutics Reports Progress on Obesity Drug ALN1003

Newsfilter

05-26Newsfilter

ALN1003 Shows Promising Results in Metabolic Disease Models

Benzinga

Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data

Newsfilter

03-02Newsfilter

Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential

Benzinga

2025-09-03Benzinga

4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week

Valuation Metrics

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT.O) is 18.48, compared to its 5-year average forward P/E of -0.96. For a more detailed relative valuation and DCF analysis to assess Alaunos Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.96

Current PE

18.48

Overvalued PE

5.77

Undervalued PE

-7.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.02

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.11

Undervalued EV/EBITDA

-0.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

3567.32

Current PS

0.00

Overvalued PS

13743.67

Undervalued PS

-6609.04

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

create swing trade setup

Intellectia · 358 candidates

Price: $1.00 - $5.00List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA5, PriceBelowMA10Week Price Change Pct: $-10.00 - $10.00Macd: bullish, positive

Ticker

Name

Market Cap$

Alaunos Therapeutics Inc

7.60M

OS Therapies Inc

53.17M

Nano-X Imaging Ltd

169.34M

Fluent Inc

107.58M

Lexicon Pharmaceuticals Inc

685.30M

Marti Technologies Inc

175.91M

Whales Holding TCRT

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alaunos Therapeutics Inc (TCRT) stock price today?

The current price of TCRT is 2.85 USD — it has decreased -6.86

What is Alaunos Therapeutics Inc (TCRT)'s business?

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

What is the price predicton of TCRT Stock?

Wall Street analysts forecast TCRT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alaunos Therapeutics Inc (TCRT)'s revenue for the last quarter?

Alaunos Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Alaunos Therapeutics Inc (TCRT)'s earnings per share (EPS) for the last quarter?

Alaunos Therapeutics Inc. EPS for the last quarter amounts to -0.52 USD, decreased -22.39

How many employees does Alaunos Therapeutics Inc (TCRT). have?

Alaunos Therapeutics Inc (TCRT) has 1 emplpoyees as of May 30 2026.

What is Alaunos Therapeutics Inc (TCRT) market cap?

Today TCRT has the market capitalization of 69.60M USD.